SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC).
作者信息
Gauci Marie-Léa, Coutzac Clélia, Houot Roch, Marabelle Aurélien, Lebbé Céleste
机构信息
Université de Paris, AP-HP Dermatology, INSERM U976, Saint Louis Hospital, Paris, France.
Centre Léon Bérard, Cancer Research Center of Lyon (CRCL), Lyon, France.
出版信息
Eur J Cancer. 2021 May;148:121-123. doi: 10.1016/j.ejca.2021.02.003. Epub 2021 Feb 18.
Abstract
摘要
相似文献
1
SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC).用于接受免疫疗法治疗的癌症患者的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗：法国癌症免疫治疗协会（FITC）的建议
Eur J Cancer. 2021 May;148:121-123. doi: 10.1016/j.ejca.2021.02.003. Epub 2021 Feb 18.
2
Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors.BNT162b2 mRNA新冠疫苗在接受免疫检查点抑制剂治疗的癌症患者中的短期安全性
Lancet Oncol. 2021 May;22(5):581-583. doi: 10.1016/S1470-2045(21)00155-8. Epub 2021 Apr 1.
3
COVID-19 vaccines: modes of immune activation and future challenges.COVID-19 疫苗：免疫激活模式和未来挑战。
Nat Rev Immunol. 2021 Apr;21(4):195-197. doi: 10.1038/s41577-021-00526-x.
4
SARS-CoV-2 vaccines for cancer patients: a call to action.癌症患者的 SARS-CoV-2 疫苗：行动呼吁。
Eur J Cancer. 2021 May;148:316-327. doi: 10.1016/j.ejca.2021.01.046. Epub 2021 Feb 25.
5
Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.尽管接种了mRNA疫苗加强针，但仍出现了新冠病毒奥密克戎变异株突破性感染。
Lancet. 2022 Feb 12;399(10325):625-626. doi: 10.1016/S0140-6736(22)00090-3. Epub 2022 Jan 18.
6
Fast Development of High-Quality Vaccines in a Pandemic.大流行期间高质量疫苗的快速研发
Chest. 2021 Jul;160(1):e1-e3. doi: 10.1016/j.chest.2021.03.063. Epub 2021 Apr 20.
7
Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data.mRNA-BNT162b2、mRNA-1273 和 ChAdOx1 nCoV-19 疫苗在医护人员中预防 COVID-19 的有效性：基于监测数据的观察性研究。
Clin Microbiol Infect. 2021 Nov;27(11):1699.e5-1699.e8. doi: 10.1016/j.cmi.2021.06.043. Epub 2021 Jul 13.
8
Newborns' passive humoral SARS-CoV-2 immunity following heterologous vaccination of the mother during pregnancy.孕期母亲进行异源疫苗接种后新生儿的被动体液性新冠病毒免疫
Am J Obstet Gynecol. 2022 Feb;226(2):261-262. doi: 10.1016/j.ajog.2021.10.006. Epub 2021 Oct 11.
9
Can families believe the accuracy of websites' information regarding COVID-19 vaccines' side effects?家庭能否相信网站上关于新冠疫苗副作用信息的准确性？
Arch Dis Child. 2022 Mar;107(3):e24. doi: 10.1136/archdischild-2021-323259. Epub 2021 Dec 14.
10
Thrombocytopenia after COVID-19 vaccination.新冠疫苗接种后的血小板减少症。
J Autoimmun. 2021 Sep;123:102712. doi: 10.1016/j.jaut.2021.102712. Epub 2021 Jul 27.
引用本文的文献
1
Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors.免疫检查点抑制剂治疗的癌症患者接种第三剂 SARS-CoV-2 mRNA-BNT162b2 疫苗后的免疫相关不良事件和疾病结局。
Cancer Immunol Immunother. 2023 Oct;72(10):3217-3228. doi: 10.1007/s00262-023-03489-1. Epub 2023 Jul 10.
2
Concerns related to the interactions between COVID-19 vaccination and cancer/cancer treatment were barriers to complete primary vaccination series among Chinese cancer patients: A multicentre cross-sectional survey.中国癌症患者完成初级疫苗接种系列的障碍与 COVID-19 疫苗接种和癌症/癌症治疗之间的相互作用有关：一项多中心横断面调查。
Hum Vaccin Immunother. 2023 Aug 1;19(2):2222648. doi: 10.1080/21645515.2023.2222648. Epub 2023 Jun 14.
3
Immune Response to SARS-CoV-2 Vaccination in Cancer Patients: A Prospective Study.癌症患者对SARS-CoV-2疫苗接种的免疫反应：一项前瞻性研究。
Cureus. 2023 Apr 1;15(4):e37014. doi: 10.7759/cureus.37014. eCollection 2023 Apr.
4
COVID vaccine recommendations in dermatologic patients on immunosuppressive agents: Lessons learned from pandemic.皮肤科免疫抑制患者的 COVID 疫苗推荐：大流行期间的经验教训。
J Cosmet Dermatol. 2022 Dec;21(12):6568-6573. doi: 10.1111/jocd.15448. Epub 2022 Dec 12.
5
Diabetic ketoacidosis shortly after COVID-19 vaccination in a non-small-cell lung cancer patient receiving combination of PD-1 and CTLA-4 inhibitors: A case report.一名接受PD-1和CTLA-4抑制剂联合治疗的非小细胞肺癌患者在接种新冠疫苗后不久发生糖尿病酮症酸中毒：病例报告
Thorac Cancer. 2022 Apr;13(8):1220-1223. doi: 10.1111/1759-7714.14352. Epub 2022 Feb 14.
6
Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis.评估癌症患者的 COVID-19 疫苗反应：一项中期分析。
Eur J Cancer. 2021 Dec;159:259-274. doi: 10.1016/j.ejca.2021.10.013. Epub 2021 Oct 25.
7
Cancer or COVID-19? A Review of Recommendations for COVID-19 Vaccination in Cancer Patients.癌症还是 COVID-19？癌症患者 COVID-19 疫苗接种建议的综述。
Curr Treat Options Oncol. 2021 Sep 13;22(10):95. doi: 10.1007/s11864-021-00903-7.
8
Severe cutaneous adverse reaction following COVID-19 vaccination and immunotherapy: a second hit?新型冠状病毒肺炎疫苗接种和免疫治疗后的严重皮肤不良反应：二次打击？
Clin Exp Dermatol. 2022 Jan;47(1):149-151. doi: 10.1111/ced.14852. Epub 2021 Aug 13.
9
Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer.当前提高正在接受癌症积极治疗的患者对 SARS-CoV-2 疫苗效力的观点。
Eur J Cancer. 2021 Sep;154:66-72. doi: 10.1016/j.ejca.2021.06.008. Epub 2021 Jun 18.
10
[COVID-19 Vaccination for Cancer Patients: Progress and Preliminary Recommendations].[癌症患者的 COVID-19 疫苗接种：进展与初步建议]
Zhongguo Fei Ai Za Zhi. 2021 Jun 20;24(6):377-383. doi: 10.3779/j.issn.1009-3419.2021.101.18. Epub 2021 May 24.
本文引用的文献
1
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
2
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
3
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
4
COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry.癌症患者中的 COVID-19：临床特征和结局——LEOSS 登记处的分析。
Ann Hematol. 2021 Feb;100(2):383-393. doi: 10.1007/s00277-020-04328-4. Epub 2020 Nov 7.
5
Factors associated with COVID-19-related death using OpenSAFELY.使用 OpenSAFELY 分析与 COVID-19 相关死亡的因素。
Nature. 2020 Aug;584(7821):430-436. doi: 10.1038/s41586-020-2521-4. Epub 2020 Jul 8.
6
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?抗 CD20 治疗会影响 SARS-CoV-2 疫苗的疗效吗？
Eur J Cancer. 2020 Sep;136:4-6. doi: 10.1016/j.ejca.2020.06.017. Epub 2020 Jun 25.
7
Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1.接受靶向PD-1或PD-L1的检查点抑制剂治疗的癌症患者中流感疫苗接种的免疫原性和安全性。
Ann Oncol. 2020 Jul;31(7):959-961. doi: 10.1016/j.annonc.2020.03.290. Epub 2020 Mar 26.
8
Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.关于新型冠状病毒肺炎和使用免疫检查点抑制剂进行抗癌治疗的争议。
Immunotherapy. 2020 Apr;12(5):269-273. doi: 10.2217/imt-2020-0067. Epub 2020 Mar 26.
9
Association of increased influenza vaccination in health care workers with a reduction in nosocomial influenza infections in cancer patients.医护人员流感疫苗接种增加与癌症患者医院内流感感染减少之间的关联。
Am J Infect Control. 2016 Sep 1;44(9):1016-21. doi: 10.1016/j.ajic.2016.03.024. Epub 2016 May 5.
Zotero 插件